An open-label, single-arm, phase I study to assess the safety, efficacy, and biomarker effects of OMT-110 in patients with refractory colorectal cancer.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Soobong | - |
dc.contributor.author | Lee, Haejun | - |
dc.contributor.author | Jeong, Keun-Yeong | - |
dc.contributor.author | Baek, Jeong-Heum | - |
dc.contributor.author | Chang, Chong-Hwan | - |
dc.date.available | 2021-03-04T00:40:21Z | - |
dc.date.created | 2021-03-04 | - |
dc.date.issued | 2020-05 | - |
dc.identifier.issn | 0732-183X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/80261 | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL ONCOLOGY | - |
dc.title | An open-label, single-arm, phase I study to assess the safety, efficacy, and biomarker effects of OMT-110 in patients with refractory colorectal cancer. | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000560368305393 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL ONCOLOGY, v.38, no.15 | - |
dc.description.isOpenAccess | N | - |
dc.citation.title | JOURNAL OF CLINICAL ONCOLOGY | - |
dc.citation.volume | 38 | - |
dc.citation.number | 15 | - |
dc.contributor.affiliatedAuthor | Baek, Jeong-Heum | - |
dc.type.docType | Meeting Abstract | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.